Roots Analysis has done a detailed study on Drug Repurposing Service Providers Market, 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
To order this 250+ page report, which features 100+ figures and 140+ tables, please visit this link
Key Market Insights
- More than 60 industry players across the world are presently engaged in providing services for the repurposing of therapeutics
- The dataset features a variety of CRO, big data / analytics and technology-based service providers, offering repurposing services by using different type of repurposing approaches and drug molecules
- Over 1,700 discontinued clinical studies of therapeutics can be considered as potential candidates for repurposing
- In the pursuit of obtaining an edge within this emerging and highly competitive market landscape, service providers are actively exploring the therapeutic potential of the existing approved drugs by providing the necessary support to drug developers in identifying / predicting prospective drug candidates for repurposing.
- Over time, recent initiatives have been undertaken by big pharma players across the world for the discovery and development of repurposed drugs
- Several organizations have extended financial support to aid research efforts in this domain; the current focus is on investigation of novel immune checkpoint pathways / targets for coronavirus disease
- The growing interest in this field is also reflected by the 10+ partnerships have been signed in the last three years, involving both international and indigenous stakeholders
- The future market, based on the revenue generation potential of repurposed drugs, is anticipated to be distributed across different disease areas and key geographical regions
- In the long term, the opportunity is likely to be segmented across type of repurposing approaches, purpose of repurposing and type of drug molecule
For more information, please visit https://www.rootsanalysis.com/reports/drug-repurposing-service-provides.html
Table of Contents
- PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Drug Repurposing
3.2.1 History of Drug Repurposing
3.2.2 Strategies for Drug Repurposing
3.3. Repurposing versus the Traditional Drug Discovery
3.4. Benefits and Challenges Associated with Drug Repurposing
3.5. Drug Repurposing Service Providers
- MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Drug Repurposing Service Provider: Overall Market Landscape of Contract Research Organizations (CROs)
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Company Size and Location of Headquarters
4.2.5. Analysis by Type of Drug Molecule
4.2.6. Analysis by Status of Drug
4.2.7. Analysis by Repurposing Approach
4.2.8. Analysis by Services Offered
4.3. Drug Repurposing Service Provider: Overall Market Landscape of Big Data / Analytics Service Providers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Company Size and Location of Headquarters
4.3.5. Analysis by Technology Specifications
4.3.6. Analysis by Type of Drug Molecule
4.3.7. Analysis by Status of Drug
4.3.8. Analysis by Repurposing Approach
4.3.9. Analysis by Services Offered
4.4. Drug Repurposing Service Provider: Overall Market Landscape of Technology Providers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Location of Headquarters
4.4.4. Analysis by Company Size and Location of Headquarters
4.4.5. Analysis by Technology Specifications
4.4.6. Analysis by Type of Drug Molecule
4.4.7. Analysis by Status of Drug
4.4.8. Analysis by Repurposing Approach
4.2.9. Analysis by Services Offered
- ROLE OF NON-PROFIT / ACADEMIC ORGANIZATIONS
5.1. Chapter Overview
5.2. Drug Repurposing Service Providers: List of Non-Profit Organizations
5.3. Stakeholder Profiles
5.3.1. Cures Within Reach
5.3.2. GlobalCures
5.3.3. Anticancer Fund
5.3.4. National Center for Advancing Translational Sciences
5.4. Drug Repurposing Service Providers: List of Academic Organizations
- COMPANY PROFILES
6.1. Chapter Overview
6.2. Company Profiles for CROs
6.2.1. Auxiliis Pharma
6.2.1.1. Company Overview
6.2.1.2. Service Portfolio
6.2.1.3. Future Outlook
6.2.2. ChemBio Discovery Solutions
- 2.2.1. Company Overview
- 2.2.2. Service Portfolio
- 2.2.3. Future Outlook
6.2.3. GVK BIO
6.2.3.1. Company Overview
6.2.3.2. Technology Overview
6.2.3.3. Service Portfolio
6.2.3.4. Future Outlook
6.2.4. Iris Pharma
6.2.4.1. Company Overview
6.2.4.2. Service Portfolio
6.2.4.3. Future Outlook
6.2.5. Physiogenex
6.2.5.1. Company Overview
6.2.5.2. Service Portfolio
6.2.5.3. Future Outlook
6.3. Company Profiles for Big Data / Analytics Service Providers
6.3.1. Excelra
6.3.1.1. Company Overview
6.3.1.2. Technology Overview
6.3.1.3. Service Portfolio
6.3.1.4. Future Outlook
6.3.2. Smart Pharma
6.3.2.1. Company Overview
6.3.2.2. Technology Overview
6.3.2.3. Service Portfolio
6.3.2.4. Future Outlook
6.4. Company Profiles for Technology Providers
6.4.1. Lantern Pharma
6.4.1.1. Company Overview
6.4.1.2. Technology Overview
6.4.1.3. Service Portfolio
6.4.1.4. Future Outlook
6.4.2. Panxome
6.4.2.1. Company Overview
6.4.2.2. Technology Overview
6.4.2.3. Service Portfolio
6.4.2.4. Future Outlook
6.4.3. Pharmacelera
6.4.3.1. Company Overview
6.4.3.2. Technology Overview
6.4.3.3. Service Portfolio
6.4.3.4. Future Outlook
6.4.4. Socium
6.4.4.1. Company Overview
6.4.4.2. Service Portfolio
6.4.4.3. Future Outlook
6.4.5. SOM Biotech
6.4.5.1. Company Overview
6.4.5.2. Technology Overview
6.4.5.3. Service Portfolio
6.4.5.4. Future Outlook
- PARTNERSHIPS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Drug Repurposing Service Providers: List of Partnerships
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Year and Type of Partnership
7.3.4. Analysis by Type of Technology / Platform Used
7.3.5. Analysis by Therapeutic Area
7.3.6. Geographical Analysis
7.3.6.1. Continent-wise Distribution
7.3.6.2. Country-wise Distribution
- BIG PHARMA INITIATIVES
8.1. Chapter Overview
8.2. List of Drug Repurposing Initiatives of Big Pharma Players
8.2.1. Analysis by Number of Initiatives
8.2.2. Analysis by Year of Initiative
8.2.3. Analysis by Type of Initiative
8.2.4. Analysis by Therapeutic Area
8.2.5. Analysis by Type of Drug Molecule
8.2.6. Big Pharma Activity: Analysis by Year of Initiative and Company
8.2.7. Big Pharma Activity: Analysis by Type of Drug Molecule and Company
8.3. Competitive Benchmarking of Big Pharma Players
8.3.1. Big Pharma Investment Summary
8.4. Initiatives Undertaken by Leading Players
8.4.1. Initiatives Undertaken by AbbVie
8.4.1.1. In-House Initiatives
8.4.2. Initiatives Undertaken by Astellas Pharma
8.4.2.1. Initiatives in Collaboration with Other Stakeholders
8.4.2.2. Recent Regulatory Approvals of Repurposed Drugs
8.4.3. Initiatives Undertaken By AstraZeneca
8.4.3.1. In-House Initiatives
8.4.3.2. Initiatives in Collaboration with Other Stakeholders
8.4.4. Initiatives Undertaken by Bayer
8.4.4.1. Initiatives in Collaboration with Other Stakeholders
8.4.5. Initiatives Undertaken by Boehringer Ingelheim
8.4.5.1. Initiatives in Collaboration with Other Stakeholders
8.4.5.2. Recent Regulatory Approvals of Repurposed Drugs
8.4.6. Initiatives Undertaken by Eli Lilly
8.4.6.1. Initiatives in Collaboration with Other Stakeholders
8.4.6.2. Recent Regulatory Approvals of Repurposed Drugs
8.4.7. Initiatives Undertaken by Gilead Sciences
8.4.7.1. Recent Regulatory Approvals of Repurposed Drugs
8.4.8. Initiatives Undertaken by GSK
8.4.8.1. In-House Initiatives
8.4.8.2. Initiatives in Collaboration with Other Stakeholders
8.4.9. Initiatives Undertaken by Novartis
8.4.9.1. In-House Initiatives
8.4.9.2. Initiatives in Collaboration with Other Stakeholders
8.4.9.3. Recent Regulatory Approvals of Repurposed Drugs
8.4.10. Initiatives Undertaken by Roche
8.4.10.1. In-House Initiatives
8.4.10.2. Initiatives in Collaboration with Other Stakeholders
8.4.11. Initiatives Undertaken by Sanofi
8.4.11.1. In-House Initiatives
8.4.11.2. Recent Regulatory Approvals of Repurposed Drugs
8.5. Other Big Pharma Players
8.5.1. Initiatives Undertaken by Pfizer
8.5.1.1. Initiatives in Collaboration with Other Stakeholders
- CASE STUDY: DISCONTINUED DRUG DEVELOPMENT PROGRAMS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Drug Repurposing: Discontinued Clinical Trials
9.3.1. Analysis by Trial Status
9.3.2. Analysis by Trial Phase
9.3.3. Analysis by Cause of Discontinuation of Clinical Research
9.3.4. Analysis by Therapeutic Area
9.3.5. Analysis by Trial Status and Location of Trial Site
9.3.6. Analysis by Phase Distribution versus Cause of Discontinuation of Clinical Research
9.3.7. Analysis by Trial Phase and Target Therapeutic Area
9.3.8. Analysis by Cause of Discontinuation of Clinical Research and Target Therapeutic Area
9.4. Discontinued Clinical Trials Analysis: Key Therapeutic Area
9.4.1. Discontinued Clinical Trials: Oncology Disorders
9.4.1.1. Analysis by Trial Status
9.4.1.2. Analysis by Trial Phase
9.4.1.3. Analysis by Cause of Discontinuation of Clinical Research
9.4.1.4. Analysis by Trial Status and Location of Trial Site
9.4.2. Discontinued Clinical Trials Analysis: CNS Disorders
9.4.2.1. Analysis by Trial Status
9.4.2.2. Analysis by Trial Phase
9.4.2.3. Analysis by Cause of Discontinuation of Clinical Research
9.4.2.4. Analysis by Trial Status and Location of Trial Site
9.4.3. Discontinued Clinical Trials Analysis: Metabolic Disorders
9.4.3.1. Analysis by Trial Status
9.4.3.2. Analysis by Trial Phase
9.4.3.3. Analysis by Cause of Discontinuation of Clinical Research
9.4.3.4. Analysis by Trial Status and Location of Trial Site
9.4.4. Discontinued Clinical Trials Analysis: Infectious Disorders
9.4.4.1. Analysis by Trial Status
9.4.4.2. Analysis by Trial Phase
9.4.4.3. Analysis by Cause of Discontinuation of Clinical Research
9.4.4.4. Analysis by Trial Status and Location of Trial Site
9.4.5. Discontinued Clinical Trials Analysis: Autoimmune Disorders
9.4.5.1. Analysis by Trial Status
9.4.5.2. Analysis by Trial Phase
9.4.5.3. Analysis by Cause of Discontinuation of Clinical Research
9.4.5.4. Analysis by Trial Status and Location of Trial Site
9.5. List of Potential Drug Candidates
- COST SAVING ANALYSIS
10.1. Chapter Overview
10.2. Cost Saving Potential
10.2.1. Opinion of Industry Experts
10.3. Key Therapeutic Areas
10.3.1. Oncology Disorders
10.3.2. Neurological Disorders
10.3.3. Metabolic Disorders
10.3.4. Infectious Diseases
10.3.5. Rare Disorders
10.4. Concluding Remarks
- MARKET FORECAST AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions
11.3. Forecast Methodology
11.4. Overall Drug Repurposing Services Market, 2020-2030
11.4.1. Drug Repurposing Services Market: Distribution by Type of Drug Molecule, 2020, 2025 and 2030
11.4.1.1. Drug Repurposing Services Market for Small Molecules, 2020-2030
11.4.1.2. Drug Repurposing Services Market for Biologics, 2020-2030
11.4.2. Drug Repurposing Services Market: Distribution by Type of Repurposing Approach, 2020-2030
11.4.2.1. Drug Repurposing Services Market using Disease-Centric Approach, 2020-2030
11.4.2.2. Drug Repurposing Services Market using Target-Centric Approach, 2020-2030
11.4.2.3. Drug Repurposing Services Market using Drug-Centric Approach, 2020-2030
11.4.3. Drug Repurposing Services Market: Distribution by Therapeutic Area, 2020, 2025 and 2030
11.4.3.1. Drug Repurposing Services Market for Different Therapeutic Area, 2020-2030
11.4.3.2. Drug Repurposing Services Market for Same Therapeutic Area, 2020-2030
11.4.4. Drug Repurposing Services Market: Distribution by Geography, 2020-2030
11.4.4.1. Drug Repurposing Services Market in North America, 2020-2030
11.4.4.2. Drug Repurposing Services Market in Europe, 2020-2030
11.4.4.3. Drug Repurposing Services Market in Asia Pacific and RoW, 2020-2030
- COVID-19 IMPACT ON DRUG REPURPOSING SERVICE PROVIDERS MARKET
12.1. Chapter Overview
12.2. Current Opinions and Recuperative Initiatives of Key Players
12.2.1. Excelra
12.2.2. GVK Bio
12.2.3. Biovista
12.2.4. Evotec
12.3. Recuperative Strategies for Service Providers
12.3.1. Strategies for Implementation in the Short / Mid Term
12.3.2. Strategies for Implementation in the Long Term
- RECENT ADVANCEMENTS AND TRENDS IN OUTSOURCING OF DRUG REPURPOSING
13.1. Chapter Overview
13.2. Shift from One-Time Contracts to Strategic Partnerships
13.3. Adoption of New and Innovative Technologies
13.3.1. Artificial Intelligence
13.3.2. Next Generation Drug Repurposing Techniques
13.4. Focus on Niche Therapeutic Areas
13.5. Increase in Financial Inflow and Outsourcing Budgets
- INTERVIEW TRANSCRIPTS
14.1. Chapter Overview
14.2. Nandu Gattu (Senior Vice President, Excelra)
- APPENDIX 1: LIST OF POTENTIAL DRUG-INDICATION CANDIDATES FOR DRUG REPURPOSING
- APPENDIX 2: TABULATED DATA
- APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
Roots Analysis has announced the addition of “In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid, Gene Therapy and Vectors), 2020-2030 (Including Structure Based Drug Discovery, Fragment Based Drug Discovery, Ligand Based Drug Discovery, Target Based Drug Discovery / Multi-Target Drug Design, Interface Based Drug Discovery, Approaches)” report to its list of offerings.
Presently, in silico tools / approaches are available for the identification, selection and optimization of pharmacological leads.
in fact, the predictive power of such solutions has been demonstrated to enable researchers to bypass the traditional experimental screening of billions of molecules against hundreds of biological targets, thereby, allowing significant reductions in the investment of both time and resources.
It is worth mentioning that about 30% of players presently offer end-to-end drug discovery services Over 150 software solutions are currently available for use in drug discovery Around 90 companies are currently providing software tools, web applications and other technology platforms for drug discovery.
Examples of popular softwares include (in alphabetical order) FORECASTER SUITE, MOPAC2016™, PKPlus™, REAL Space Navigator, SaaS Platform and VolSurf+.
Around 40% of the companies claim to specialize in antibodies, proteins and peptidesWithin the antibodies segment, nearly 60% of in silico service offerings are focused on the discovery of monoclonal antibodies.
Therefore, the use of technology can save time and money, while providing a far better understanding of the relationships between different formulations and processes parameters.Key Drivers, Restraints, and Opportunities of AI in Pharma and Biotech MarketAdoption of artificial intelligence (AI) in the drug discovery market in developing regions such as APAC is increasing, thanks to the expansion of pharmaceutical industries by collaborating with other industries and rise in demand to reduce drug discovery time.
Furthermore, the expansion of biotechnology industries is estimated to offer significant opportunities for the market.An estimated 50% of U.S. citizens are affected by at least one chronic condition; consequently, the pharmaceutical segment of the healthcare industry is projected to be positively impacted by the expected trend of AI adoption.All top 10 so-called giant pharma companies (namely Novartis, Roche, Pfizer, Merck, AstraZeneca, GlaxoSmithKline, Sanofi, Abbvie, Bristol-Myers Squibb, and Johnson & Johnson) have either expressly collaborated with or acquired AI technologies to take advantage of the opportunities AI brings to the table.
Industry leaders are presently focused on the development of more efficient methods, and machine learning is emerging as a possible solution.The current machine learning initiatives of the top five pharmaceutical and biotechnology companies reveal trends within the following areas:Digital coaching solutions – Utilization of web-based technologies to simulate one-on-one coaching sessions so that all patients can have the benefit of a uniquely devised medication program.For instance: Johnson & Johnson’s Patient Athlete programPersonalized medicine – Personalized medicine, also called precision medicine, maybe a medical model that separates people into different groups—with medical decisions, practices, interventions, and/or products being tailored to the individual patient supported their predicted response or risk of disease.For instance.
Unlike other applications within healthcare facilities, drug discovery seems to own a clearer path to adoption.Recently, robots became more collaborative with humans and are more easily trained by moving them through the desired task.
Over time, it seems likely that an equivalent improvement in intelligence that we have seen in other areas of AI would be incorporated into physical robots.Surgical robots initially approved in the U.S. in 2000, provided ‘superpowers’ to surgeons, improving their ability to examine, create precise and minimally invasive incisions, and stitch wounds.
Common surgical procedures using robotic surgery include gynecologic surgery, prostate surgery, and head and neck surgery.Pre Book Ai In Pharma And Biotech Market Report – https://www.transparencymarketresearch.com/checkout.php?rep_id=79399=S North America to Capture Major Share of Global Market of AI in Pharma & BiotechNorth America is expected to account for a major share of the global market of AI in Pharma and Biotech due to the high prevalence of chronic diseases among the population.
Softcon Systems brings you automation solutions specific to the pharmaceutical industry – we will work with you to develop and implement ideal solutions specific to your requirements.
Automation at every point of the value chain will enable the pharma companies to get pharmaceuticals from the lab to the patient more quickly.We design systems that help pharmaceutical and biotech companies to achieve operational excellence, reduce time to market and meet all industry standards and regulations.
